Aditxt, Inc., a biotech company, has announced an amendment to its merger agreement with Evofem Biosciences, Inc. The amendment, known as Amendment No. 4, extends the end date of the merger from November 29, 2024, to January 31, 2025. This follows a series of previous amendments to the original merger agreement, which was first reported in December 2023. The merger involves Aditxt's subsidiary, Merger Sub, merging with Evofem, with the latter surviving as a wholly owned subsidiary of Aditxt. The amendment was filed with the SEC and is detailed in a Form 8-K report dated November 19, 2024. The terms of the Amended and Restated Merger Agreement remain unchanged except for the extension of the end date. The full text of Amendment No. 4 has been filed as Exhibit 10.1 with the report.

Aditxt, Inc., a biotech company, has announced an amendment to its merger agreement with Evofem Biosciences, Inc. The amendment, known as Amendment No. 4, extends the end date of the merger from November 29, 2024, to January 31, 2025. This follows a series of previous amendments to the original merger agreement, which was first reported in December 2023. The merger involves Aditxt's subsidiary, Merger Sub, merging with Evofem, with the latter surviving as a wholly owned subsidiary of Aditxt. The amendment was filed with the SEC and is detailed in a Form 8-K report dated November 19, 2024. The terms of the Amended and Restated Merger Agreement remain unchanged except for the extension of the end date. The full text of Amendment No. 4 has been filed as Exhibit 10.1 with the report.